companies developing glp 1 drugs Solving the Unmet Needs in Obesity Treatment | Obesity Pulse 2025’s Breakthrough GLP-1 Obesity Treatments:

Diabetic patients should have a baseline eye examination around the time of GLP-1/GIP agonist treatment initiation to determine the level of retinopathy and presence of DME

With this approval, and by launching a generic for Saxenda, we will provide patients in the US the first ever generic GLP-1 product specifically indicated for weight loss, said Ernie Richardsen, senior vice president, Head of US Commercial Generics at Teva

The team will study the effects of GLP-1 drugs on five disproportionately burdened populations: racially minoritized groups, individuals of low socioeconomic status, rural and non-metro populations, people living with disabilities, and sexual and gender minorities

The SURPASS-CVOT trial is a phase 3, randomized, double-blind cardiovascular outcomes trial that will assess tirzepatide for both non-inferiority and superiority against dulaglutide. For dulaglutide, this effect is already proven: According to the Trulicity website, the drug may be used in adults with type 2 diabetes to reduce the risk of major cardiovascular events (problems having to do with the heart and blood vessels) such as death, heart attack, or stroke in people who have heart disease or multiple cardiovascular risk factors. How do I know which medication is right for me

Women should practice front-to-back wiping after bowel movements to prevent bacterial contamination from the rectal area